0013820 2026 RIV GB eng J
Čuřík, Nikola - Láznička, Adam - Křížková, Jitka - Suchánková, Pavla - Vávrová, A. - Polívková, Václava - Pokorná, E. - Semerák, Pavel - Burda, Pavel - Kužílková, D. - Kalina, T. - Hochhaus, A. - Machová Poláková, Kateřina^G
Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia.
Leukemia. Vol. 39, no. 10 (2025), s. 2555-2558. ISSN 0887-6924
Institucionální podpora: RVO:00023736
Klíčová slova: venetoclax * CML * ponatinib
Cite Score: 18.500, rok: 2024; SJR: 3.458, rok: 2024; IF: 13.4, rok: 2024
DOI: 10.1038/s41375-025-02732-1

Anotace: Asciminib, an allosteric inhibitor specifically targeting the myristoyl pocket of BCR::ABL1, has expanded therapeutic options for heavily pretreated patients with chronic myeloid leukemia (CML), and for those with the BCR::ABL1 T315I mutation. Several clinical studies evaluating asciminib in frontline CML therapy are currently ongoing (e.g., ASCI4FIRST, ASCI4START, ASCEND), with promising preliminary results indicating superior efficacy, improved tolerability, and a lower rate of treatment discontinuation due to toxicity compared to ATP-competitive inhibitors However, clinical trials of asciminib in both advanced-line and first-line CML treatment also report the emergence of resistance, often due to acquired or persisting mutations in BCR::ABL1. The full spectrum of these mutations remains unidentified, underscoring the need for further investigation and the exploration of backup therapeutic strategies, including combination therapies.